Electromed (ELMD)
XASE:ELMD
Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$24.83
$0.65(2.15%)
At close: 4:00 PM EST
$24.83
$0.65(2.15%)
Day’s Range― - ―
52-Week Range$17.73 - $40.00
Previous CloseN/A
Volume34.94K
Average Volume (3M)72.98K
Market Cap
$343.29M
Enterprise Value$290.54M
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)34.0
Beta0.68
Next Earnings
Sep 01, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding8,280,064
10 Day Avg. Volume55,799
30 Day Avg. Volume72,981
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.24
Price to Sales (P/S)2.86
P/FCF Ratio16.53
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue4.05
Enterprise Value/Gross Profit5.16
Enterprise Value/Ebitda19.66
Forecast
1Y Price Target
$38.00Price Target Upside53.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.17
Revenue Forecast (FY)$73.33M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~78% gross margins indicate durable product-level profitability from the SmartVest system and consumables, supporting persistent operating leverage. High margins provide cash to invest in sales, R&D, and marketing and cushion reimbursement pressure over the medium term.
Debt-free, Liquid Balance SheetA zero-debt capital structure with meaningful cash and working capital gives Electromed financial flexibility to weather reimbursement timing, fund sales expansion, complete buybacks or invest in ops. It materially lowers solvency risk and preserves optionality over the next several quarters.
Structural Operational ImprovementsePrescribe adoption and completed manufacturing optimization cut fulfillment time and scaling friction, improving cash conversion and patient access. These process changes are durable operational levers that raise capacity, reduce costs per order and support faster geographic expansion.
Bears Say
Salesforce-dependent GrowthGrowth materially depends on hiring and ramping direct sales reps; execution risk includes recruiting, training and variable rep productivity. Delays or higher-than-expected ramp times can slow revenue expansion and compress expected operating leverage over several quarters.
Historical Cash-flow VolatilityWhile recent TTM cash conversion aligns with earnings, prior periods showed negative operating and free cash flow. Working-capital swings and investment timing have produced volatile cash generation, posing a recurring risk to funding cadence for growth or returns.
Limited Revenue Diversification & Guideline RiskCore revenue concentrates in direct homecare; hospital and distributor channels remain small, and broader adoption hinges on payer coverage and formal clinical guidelines. Dependence on DME reimbursement and guideline progress creates structural adoption and revenue-concentration risk.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $17.73 and its highest was $40.00 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $343.29M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Sep 01, 2026 which is in 65 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on May 12, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.1.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Undervalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.32.
How many shares outstanding does Electromed have?
Electromed has 8,280,064 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.35 in its last earnings report, beating expectations of $0.25. Following the earnings report the stock price went up 25.11%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (53.04% Upside)
$38.00 (53.04% Upside)
Blogger Sentiment
Bullish
ELMD Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.32%
12-Months-Change
Fundamentals
Return on Equity
22.14%
Trailing 12-Months
Asset Growth
13.39%
Trailing 12-Months
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Company Deck
ELMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong, broad-based financial performance (double-digit revenue growth, high operating leverage, margin durability), improved operational capability (completed manufacturing optimization, ePrescribe adoption), a healthy balance sheet (cash, no debt) and a large addressable bronchiectasis market supported by active clinical and digital outreach. Challenges include modest non-core revenue, reliance on ramping sales rep headcount for incremental growth, slowed share repurchases due to macro uncertainty, and remaining uncertainty on guideline publication and conversion rates from clinician engagement. Overall, the positives (robust revenue and profit expansion, operational wins, market opportunity) substantially outweigh the negatives.View all ELMD earnings summariesELMD Stock 12 Month Forecast
Average Price Target
$38.00
▲(53.04% Upside)
Technical Analysis
Ownership Overview
7.18% Insiders
10.32% Mutual Funds
16.67% Other Institutional Investors
57.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---